Novartis AG ADR (NVS)vsPharming Group NV (PHAR)
NVS
Novartis AG ADR
$161.93
+0.38%
HEALTHCARE · Cap: $303.67B
PHAR
Pharming Group NV
$12.29
-0.08%
HEALTHCARE · Cap: $867.74M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 14732% more annual revenue ($57.36B vs $386.75M). NVS leads profitability with a 17.5% profit margin vs 6.3%. NVS trades at a lower P/E of 30.7x. PHAR earns a higher WallStSmart Score of 55/100 (C).
NVS
Hold48
out of 100
Grade: D+
PHAR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.93
$66.37 premium
Margin of Safety
-32.3%
Fair Value
$11.77
Current Price
$12.29
$0.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Strong operational efficiency at 33.9%
Earnings expanding 74.9% YoY
Reasonable price relative to book value
Revenue surging 20.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 3.4% — below average capital efficiency
6.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : PHAR
The strongest argument for PHAR centers on Operating Margin, EPS Growth, Price/Book. Revenue growth of 20.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : PHAR
The primary concerns for PHAR are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while PHAR is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
PHAR is growing revenue faster at 20.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
PHAR scores higher overall (55/100 vs 48/100) and 20.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Pharming Group NV
HEALTHCARE · BIOTECHNOLOGY · USA
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?